Literature DB >> 24118918

In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.

Da-Peng Dai1, Shuang-Hu Wang, Pei-Wu Geng, Guo-Xin Hu, Jian-Ping Cai.   

Abstract

Of the 57 reported CYP2C9 alleles, to date, 36 of them have been identified in the Chinese population. The aim of this study was to assess the catalytic characteristics of these allelic isoforms and their effects on the metabolism of glimepiride in vitro. Baculovirus-mediated expressing system was used to highly express wild-type and the 35 CYP2C9 allelic variants in insect cell microsomes. Then, the enzymatic characteristics of each variant were evaluated using glimepiride as the substrate. Reactions were performed at 37°C with the insect microsomes and 0.125-10 μM glimepiride for 40 min. After termination, the products were extracted and used for signal collection by LC-MS/MS. Of the 36 tested CYP2C9 allelic isoforms, only four variants (CYP2C9.40, CYP2C9.47, CYP2C9.51 and CYP2C9.54) exhibited similar relative clearance values to that of wild-type CYP2C9.1. In addition, one variant (CYP2C9.36) showed a higher intrinsic clearance value than the wild-type protein, while the remaining 30 CYP2C9 allelic isoforms exhibited significantly decreased clearance values (from 0.1% to 87.2%) compared to CYP2C9.1. This study provided the most comprehensive data on the enzymatic activities of all reported CYP2C9 variants in the Chinese population with regard to the commonly used antidiabetic drug, glimepiride. Our results indicate that most of the tested rare alleles significantly decrease the catalytic activity of CYP2C9 variants towards glimepiride hydroxylation in vitro.
© 2013 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24118918     DOI: 10.1111/bcpt.12159

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  10 in total

1.  The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro.

Authors:  Pei-Pei Pan; Qing-Hua Weng; Chen-Jian Zhou; Yan-Li Wei; Li Wang; Da-Peng Dai; Jian-Ping Cai; Guo-Xin Hu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-05       Impact factor: 2.441

2.  Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19.

Authors:  Sandhya Devarajan; Irene Moon; Ming-Fen Ho; Nicholas B Larson; Drew R Neavin; Ann M Moyer; John L Black; Suzette J Bielinski; Steven E Scherer; Liewei Wang; Richard M Weinshilboum; Joel M Reid
Journal:  Drug Metab Dispos       Date:  2019-02-11       Impact factor: 3.922

3.  The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide.

Authors:  L Chen; J H Li; V Kaur; A Muhammad; M Fernandez; M S Hudson; A B Goldfine; J C Florez
Journal:  Diabet Med       Date:  2019-11-25       Impact factor: 4.359

4.  In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine.

Authors:  Feifei Chen; Hui Jiang; Jia Xu; Shuanghu Wang; Deru Meng; Peiwu Geng; Dapeng Dai; Quan Zhou; Yunfang Zhou
Journal:  Drug Des Devel Ther       Date:  2020-11-10       Impact factor: 4.162

Review 5.  Individualized medicine enabled by genomics in Saudi Arabia.

Authors:  Muhammad Abu-Elmagd; Mourad Assidi; Hans-Juergen Schulten; Ashraf Dallol; Peter Pushparaj; Farid Ahmed; Stephen W Scherer; Mohammed Al-Qahtani
Journal:  BMC Med Genomics       Date:  2015-01-15       Impact factor: 3.063

6.  Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats.

Authors:  Jiquan Shen; Bo Wang; Shuanghu Wang; Feifei Chen; Deru Meng; Hui Jiang; Yunfang Zhou; Peiwu Geng; Quan Zhou; Bin Liu
Journal:  Drug Des Devel Ther       Date:  2020-06-04       Impact factor: 4.162

7.  Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.

Authors:  Peng-Fei Tang; Xiang Zheng; Xiao-Xia Hu; Cheng-Cheng Yang; Zhe Chen; Jian-Chang Qian; Jian-Ping Cai; Guo-Xin Hu
Journal:  Drug Des Devel Ther       Date:  2020-11-24       Impact factor: 4.162

8.  Functional characterization of the defective CYP2C9 variant CYP2C9*18.

Authors:  Jian Liu; Hao Chen; Shuang-Hu Wang; Quan Zhou; Pei-Wu Geng; Yun-Fang Zhou; Hua-Lan Wu; Hai-Feng Shi; Fang Wang; Jie-Fu Yang; Jian-Ping Cai; Da-Peng Dai
Journal:  Pharmacol Res Perspect       Date:  2021-02

9.  Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals.

Authors:  Masaki Kumondai; Akio Ito; Evelyn Marie Gutiérrez Rico; Eiji Hishinuma; Akiko Ueda; Sakae Saito; Tomoki Nakayoshi; Akifumi Oda; Shu Tadaka; Kengo Kinoshita; Masamitsu Maekawa; Nariyasu Mano; Noriyasu Hirasawa; Masahiro Hiratsuka
Journal:  J Pers Med       Date:  2021-02-02

10.  The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.

Authors:  Maor Wanounou; Chanan Shaul; Zahi Abu Ghosh; Shoshana Alamia; Yoseph Caraco
Journal:  Clin Pharmacol Ther       Date:  2022-05-05       Impact factor: 6.903

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.